TrialHeadache2021

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.

Egilius L H Spierings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.